Mabwell’s Denosumab Biosimilar Shows Similar Efficacy To Xgeva

The Phase III Trial Enrolled Solid Tumor Patients With Bone Metastasis

 
• By Urtė Fultinavičiūtė
  
X-ray of inflamed hip bone
Mabwell has multiple international partnerships for its denosumab biosimilars • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products